midostaurin

URI: https://gptkb.org/entity/midostaurin

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:chemical_compound gptkb:drug
gptkbp:approvalYear	2017
gptkbp:approvedBy	gptkb:FDA gptkb:EMA
gptkbp:ATCCode	L01EX10
gptkbp:brand	gptkb:Rydapt
gptkbp:CASNumber	gptkb:120685-11-2
gptkbp:chemicalFormula	C35H30N4O4
gptkbp:developer	gptkb:Novartis
gptkbp:eliminationHalfLife	20-40 hours
gptkbp:has_stereochemistry	yes
gptkbp:hasSMILES	COC1=C2C(=CC=C1)C3C4C2C5C(C3N(C4=O)C(=O)NC5)C(=O)NC
https://www.w3.org/2000/01/rdf-schema#label	midostaurin
gptkbp:IUPACName	(9S,10R,12R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H,6H,12H-benzo[2,3]pyrano[4,5-b]indolizine-6,12-dicarboxamide
gptkbp:KEGGID	D09913
gptkbp:legalStatus	prescription only
gptkbp:mechanismOfAction	protease inhibitor FLT3 inhibitor
gptkbp:metabolism	liver
gptkbp:molecularWeight	570.6 g/mol
gptkbp:proteinBinding	>99%
gptkbp:PubChem_CID	gptkb:CHEMBL190836 DB06616 9829520
gptkbp:routeOfAdministration	oral
gptkbp:sideEffect	nausea vomiting diarrhea edema rash febrile neutropenia
gptkbp:target	gptkb:PDGFR gptkb:KIT gptkb:VEGFR2 gptkb:FLT3
gptkbp:UNII	G2WW6L6N3J
gptkbp:usedFor	gptkb:systemic_mastocytosis gptkb:acute_myeloid_leukemia
gptkbp:bfsParent	gptkb:Rydapt
gptkbp:bfsLayer	5